July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

Dermatologists Show Lowest Turnover Intent of All Specialists

AMA data show only 19.9% of dermatologists plan to leave their current positions, compared with 40.6% of anesthesiologists.

Conexiant

June 23, 2025

What’s the Dose for Hair Regrowth?

A national survey found wide variation in intralesional corticosteroid injection techniques among US hair specialists treating different types of alopecia.

Conexiant

June 23, 2025

Remote and Ready: Rethinking COPD Care

A large meta-analysis of 33 trials found that community-based COPD management models improved lung function, exercise capacity, and symptom control compared to usual care, though quality-of-life gains were not significant.

Conexiant

June 09, 2025

New Fixed-Dose RSV Antibody Approved

The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.

Conexiant

November 01, 2024

Are Antibiotics Needed for Pediatric Pneumonia?

Nearly one in five children diagnosed with pneumonia in outpatient settings did not receive antibiotics, according to a recent study in JAMA Network Open.

Conexiant

December 13, 2024

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Conexiant

November 13, 2024

Is COPD Set to Affect 600M Globally?

GOLD 2025 highlights new pathways and advanced COPD therapies like ensifentrine and dupilumab to reduce exacerbations and address emerging COPD phenotypes.

Conexiant